Director's Message
According to Dr. Deshaies, the biopharmaceutical industry has undergone four transformative waves over the past century. The first wave combined chemistry and pharmacology that yielded structurally defined therapeutic molecules, the second introduced target-centric drug discovery, and the third brought recombinant proteins and monoclonal antibodies. The current fourth wave focuses on multispecific drugs, such as antibody drug conjugates (ADCs) and Proteolysis Targeting Chimeras (PROTACs), which engage multiple entities simultaneously. These waves have driven innovation, improved patient outcomes, and enabled more precise and effective therapies.
Modified based on Deshaies, 2020, Nature
The Center for Nextgen Therapeutics (CNGT) primarily focuses on developing multispecific drugs by leveraging the cutting edge biological and biomedical research at Baylor College of Medicine. Our mission is to accelerate the discovery and development of novel therapeutics that address unmet medical needs and improve patient outcomes.
Jin Wang, Ph.D.
Director, Center for NextGen Therapeutics
Michael E. DeBakey, M.D., Endowed Professor in Pharmacology
